Bullboard - Stock Discussion Forum Avalo Therapeutics Inc AVTX

Healthcare Biotechnology

Avalo Therapeutics, Inc. is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The Company's lead asset is AVTX-009, an anti-IL-1ß mAb, targeting inflammatory diseases. Its pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein). AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1ß (IL-1ß... see more

Add To Watchlist

NDAQ:AVTX - Post Discussion

Avalo Therapeutics Inc > Avalo Therapeutics Announces Active IND for AVTX-009, an ant

View:

Post by whytestocks on Jul 09, 2024 6:30pm

Avalo Therapeutics Announces Active IND for AVTX-009, an ant

News; $AVTX Avalo Therapeutics Announces Active IND for AVTX-009, an anti-IL-1? mAb, to Treat Hidradenitis SuppurativaFollowing FDA review, Avalo’s IND application for AVTX-009 is active allowing Avalo to proceed with its Phase 2 trial (LOTUS) to evaluate the efficacy and safety of AVTX-009 in patients with hidradenitis suppurativa WAYNE, Pa. and ROCKVILLE, Md., July 09, 2024 (GLOBE NEWSWIRE) -- Ava...AVTX - Avalo Therapeutics Announces Active IND for AVTX-009, an anti-IL-1? mAb, to Treat Hidradenitis Suppurativa